SlideShare ist ein Scribd-Unternehmen logo
1 von 6
Downloaden Sie, um offline zu lesen
Cancer Registry Poised to Support Accountable Care
Reimbursement & Strengthen the Bottom Line
Focus on quality of care and quality of data leads innovative organizations
and fiscally focused executives to increasingly turn to the cancer registry
Introduction: Accountable
Care, the Bottom Line and
the Cancer Registry
Recently profiled in the April 23, 2013 New York Times
article, “A Health Provider Strives to Keep Hospital
Beds Empty,” Advocate Health Care has embraced
accountable care and has already achieved a
two percent cost savings as a direct result.
According to the article, thus far, hospital
admissions are down six percent, and days spent
in the hospital are down nearly nine percent. To
facilitate the change, “Advocate has hired scores
of workers to coordinate care and keep an eye on
the highest-cost patients...”
According to the same NY Times article, an
estimated 428 accountable-care organizations now
cover four million Medicare enrollees and millions
more people with private insurance.
While many pundits believe the accountable care
movement could be the most meaningful recent
development in the effort to fix our nation’s health
care industry, hospital executives are only beginning
to open their eyes to the powerful role their cancer
registries can play in the quest for profitability during
and beyond the transition. Critically important, the
quality of data collection directly affects patient
outcomes and reimbursement, and executives
should take a few simple steps today to assess the
quality of their cancer registry data, begin to use
it more effectively and improve future financial
performance.
Data quality’s impact on
patient care, outcomes and
the bottom line
Suspect data affects patient outcomes, and
in accountable care organizations this also
harms financial performance. Accountable
care organizations link payments to quality
improvements and cost reductions, a practice
that will spread to cancer care soon. The deeper
hospitals move into pay for performance, the
more data their executives will need to prove
quality of care.
1
Executives should take the time to examine the
sources of their organizations’ data and how they
acquire and report that data. Turning to the best
data sources can boost reimbursement and
financial performance of cancer centers and
their parent organizations, and the best source for
data related to cancer is undoubtedly the cancer
registry department.
Cancer registries already maintain
the highest quality data
Throughout the industry, the many ways
organizations have begun to harness cancer
registry data speaks to their confidence in the
quality of that data. At some of the hospitals
and health networks that work with Care
Communications to ensure efficiency and
effectiveness in cancer registry departments,
cancer registry data has been effectively put to
use in many different ways. Already, organizations
use cancer registry data to justify new investments
in technology or medical expertise. Many use
the data to grade their own cancer center’s
performance against benchmarks, determine
if patients receive appropriate treatment, and
educate physicians on what standards of care
should be. In other instances, organizations use
the data to analyze referral patterns or better
understand their customer base. As more
organizations begin to understand the value of
this data as a competitive advantage for critical
analysis and decision making, the industry’s
growing confidence in the quality of data from the
cancer registry will most likely only continue to rise.
This makes perfect sense, considering the origin of
that data.
Abstracted by trained professionals, the cancer
registry is a reliable, yet under-utilized source of
cancer outcomes data. To ensure data quality
standards, cancer registries remain highly
regulated but offer the flexibility to be easily
expanded in an organization’s efforts to collect
additional helpful information and data that can
further enhance patient care or the organization’s
bottom line.
the heightened quality of data housed in cancer
registries can deliver a positive impact on efforts to
reduce costs and improve reimbursement.
The cancer registry should already be positioned
to help the organization, because it can efficiently
provide all required outcomes data. Unfortunately,
many organizations mistakenly overlook the
cancer registry as a quality data source and
waste extensive time and resources by recreating
much of the same data.
Beyond outcomes data, the cancer registry can be
used to determine outbound and inbound patient
referrals, which can provide an accurate assessment
of both lost and realized opportunity. For example, if
the organization has referred numerous patients to
a nearby breast surgeon for appropriate treatment,
then perhaps the organization should consider hiring
a breast surgeon. This could help ensure that the
patient can receive treatment with the organization
managing their care. Similarly, if the cancer registry
data shows numerous inbound referrals for specific
treatments, there may be an opportunity to expand
this part of the organization to ensure effective, timely
treatment for patients.
By taking simple steps today, including asking a few
simple questions to assess the current state of the
cancer registry, the already impressive quality of
cancer registry data can be further improved, along
with its impact on tomorrow’s bottom line.
Cancer registry now the definitive
source for cancer outcomes data
The cancer registry exists as the timeliest, most
complete and most accurate data source for most
accredited cancer programs and should be every
executive’s preferred source for all cancer-related
outcomes data. Revised in 2012, the ACoS CoC
standards shifted the focus of the standards to the
quality of patient care and enhanced the reporting
of cancer data to include concurrent abstracting
options with the introduction of the Rapid Quality
Reporting Systemiii
(RQRS).
Cancer registries... (cont’d)
2
Turning to the cancer registry as a trusted source
for data ensures quality, thanks to the American
College of Surgeons (ACoS) Commission on
Cancer (CoC) and its stringent regulations on data
quality. Its published standards for data qualityi
require all case abstracting to be performed
by a Certified Tumor Registrar (CTR) in a timely
manner (90 percent of cases are abstracted within
six months of the date of first contact with the
program). The standards also present mandated
follow-up rates of 80 percent for all patients
and 90 percent for recent patients, as well as
requirements for data quality and submission to
the National Cancer Data Base (NCDB).
The high quality data ensured by this governance
improves reimbursement and reduces costs,
particularly in an accountable care environment.
So, consider who is in charge of collecting the
data. Cancer registry data is collected by highly
trained Certified Tumor Registrars who have met
increasingly strenuous educational requirements,
including passing a national certification exam.
The CTR certification marks its 30th anniversary in
2013, a testament to the stability and long-term
contributions of these highly trained professionals.
Once the certification is obtained, registrars must
meet continuing education requirements to
maintain the CTR credential. CTRs are trained to:
“...correctly interpret and code cancer
diagnosis, stage, treatment, and outcomes
information for each case...”ii
The use of CTRs for data abstraction ensures that
cancer registry data is of the highest quality and
executives can trust the data as a reliable source
for informed decision making and utilize it to assist
in meeting quality parameters in multiple settings.
Value of the cancer registry
to the bottom line
Executives should understand what data their
cancer registry contains and how that data can
be easily extracted and used to help patients
and improve the organization’s bottom line. Since
data quality directly impacts patient outcomes,
to reduce costs and improve patient outcomes
and organizational performance already exists
in the cancer registry. Beyond accessing existing
data, new fields can be added to the cancer
registry data collection process to ensure that
any additional required data is accessible
moving forward.
Simple steps today, financial
rewards tomorrow
The cancer registry data assessment will help
executives better understand the current state
of their organizations’ cancer registry and what
cancer registry data can do for their organizations
today. With a solid understanding of the starting
point in hand, executives should take the following
steps to further enhance the usefulness and future
potential of the cancer registry to improve an
organization’s performance in a variety of ways.
1 Develop standard reports for data analysis.
	 These reports can be custom designed on
any data parameter collected by the cancer
registry and can aid in understanding the
who, what, when, where, why and how of an
organization’s cancer program.
2 (Executives) Become active and involved in
cancer committee meetings where these
reports can be presented.
	 Decisions on program development and
improvement can be made given your active
involvement in both data analysis review and
cancer committee attendance.
3 Ask for data.
	 Executives are often surprised to discover the
amount of data available to them that can
aid in their decision making processes.
4 Before conducting a study or chart review on
cancer care, seek out the assistance of your
cancer registry.
	 Duplication of effort can be avoided, and
many resources can be applied to other
more useful efforts.
Cancer registry now... (cont’d)
Prior to the institution of the RQRS, providers
received information 18-24 months after treatment
rendering the treatment information insufficient
to assess quality of care. To address these issues
the CoC adopted the RQRS. Currently voluntary,
RQRS could become mandatory in the future,
which would require accredited cancer programs
to report data on patients concurrently and notify
hospitals of treatment expectations. Each hospital
would then receive its year-to-date concordance
rate relative to other similar hospitals at the local,
state and national levels.
The CoC has a data use agreement in place
to use the clinical information provided by the
RQRS for the purposes of quality review and
improvement. The revised CoC standards
assist hospitals with health care operations,
including quality assurance, utilization review and
accreditation. As a result, the cancer registry now
provides the most accurate and complete source
of data on cancer treatment and outcomes
available to many health care executives.
Quickly assess the organization’s
cancer registry data
To quickly assess the quality of an organization’s
cancer registry data and its potential to boost
organizational performance today, executives
should work with their teams to answer four
simple questions:
1 What data do we currently have access to
through the cancer registry?
2 What data has been required in the past and
is it relevant for use today?
3 What data is needed today in light of new
accountability and reporting standards?
4 What, if any, additional data points should we
begin collecting to strengthen the registry’s
stature as a tool to build the bottom line?
As executives answer these questions, it should
become obvious that much of the data they need
3
Simple steps today... (cont’d)
5 Monitor timeliness of treatment.
	 If the average delay between diagnosis
and the start of treatment is extended, it
could signal a communications breakdown
between specialties or a shortage of
appointment openings for treatment, and this
could be an opportunity for a fast tracking
program.
6 Monitor the treatment mix for the
primary facilities.
	 Does the treatment mix mirror national trends?
If not, it could mean that patients aren’t
being informed of all their options before
deciding on a course of treatment; perhaps
there is a need for a more thorough patient
consultation program.
7 Examine average stage of disease
at diagnosis.
	 Are the organization’s patients being
diagnosed at later stages of disease than the
benchmarks established at the local, state,
or national level? If so, the community may
need an early screening program to provide
patients and primary care physicians with a
better education on early detection.
8 Monitor patient ages.
	 Determine the primary age groups of patients
and compare them to previous data to see if
the average age has changed. This will help
in planning and scheduling support programs
for different patient age groups.
9 Analyze the success of signature services.
	 Using rapid reporting mechanisms such as
the RQRS, executives can compare patients
who are eligible for signature services to those
who are using them to determine whether the
services should be grown (marketed, referred
and staffed) or discontinued.
10 Review patient addresses.
	 By taking a close look at patient addresses,
the organization can identify areas where
few or no patients reside, potentially signaling
an opportunity for extended community and
primary care physician outreach.  
References:
i
Commission on Cancer. Cancer Program Standards
2012: Ensuring Patient-Centered Care. American
College of Surgeons. http://www.facs.org/cancer/
coc/programstandards2012.pdf. Published
September, 2012. Accessed May 20, 2013.
ii
Commission on Cancer. Cancer Program Standards
2012: Ensuring Patient-Centered Care. American
College of Surgeons. http://www.facs.org/cancer/
coc/programstandards2012.pdf. Published
September, 2012. Accessed May 20, 2013.
iii
Commission on Cancer. The Rapid Quality
Reporting System. American College of Surgeons.
http://www.facs.org/cancer/ncdb/rqrs0509.pdf
Published April, 2009. Accessed May 20, 2013.
4
About the Author
Laurie Hebert, RHIA, CCS, CCS-P, CTR
Vice President and General Manager, Cancer Registry Services
800-458-3544, ext. 161
lhebert@care-communications.com
www.carecommunications.com/cancer_registry
As Vice President and General Manager, Cancer Registry Services at
Care Communications, Inc., Laurie Hebert is responsible for managing
client relationships, cancer registry consultants, and sales of cancer
registry services. Hebert also provides input and required oversight for
research projects that require cancer registry data. With over 20 years
of experience, Hebert has worked at various hospitals and cancer
registry facilities in a wide range of health information management
(HIM) roles.
She has published or contributed to many articles noted in national
trade publications, authored white papers related to the cancer
registry field, co-authored a study on pediatric lymphoma, and
assisted in the development of a pediatric staging form chosen by the
American College of Surgeons Commission on Cancer as a best practice tool for pediatric facilities.
Hebert is currently serving on the National Cancer Registrars Association’s (NCRA) Board of Directors as
Advocacy and Technical Practice Director-Midwest along with serving on several additional NCRA related
committees, and is the past chair of the association’s National Cancer Registrars Week Committee. She is
past president-elect of the Central Louisiana Health Information Management Association and past president
of the Southeast Louisiana Health Information Management Association.
Hebert is a member of several health care associations including the American Health Information
Management Association (AHIMA), National Cancer Registrars Association, Louisiana Health Information
Management Association (LHIMA), the Southwest Louisiana Health Information Management Association
(SWLHIMA) and the Louisiana Cancer Registrars Association (LCRA).
She received a bachelor’s degree in psychology and HIM from the University of Southwestern Louisiana.
Areas of Expertise:
l Cancer registry regulations and accreditation
l Cancer registry education and advocacy
l Data management and analysis
l Quality data collection
l Cancer studies
l Outcomes measurement
l Database outcomes improvement
5

Weitere ähnliche Inhalte

Kürzlich hochgeladen

AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectiondrhanifmohdali
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfHongBiThi1
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...Shubhanshu Gaurav
 
historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu Medical University
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfDolisha Warbi
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfHongBiThi1
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfDolisha Warbi
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxMAsifAhmad
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets barmohitRahangdale
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.pptRamDBawankar1
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Peter Embi
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismusChandrasekar Reddy
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptxNIKITA BHUTE
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communicationskatiequigley33
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisSujoy Dasgupta
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)kishan singh tomar
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyMedicoseAcademics
 

Kürzlich hochgeladen (20)

AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissection
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
 
historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
 
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets bar
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024
 
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismus
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communications
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosis
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)
 
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before Pregnancy
 

Cancer Registry Supports the Growth of Accountable Care Organizations

  • 1. Cancer Registry Poised to Support Accountable Care Reimbursement & Strengthen the Bottom Line Focus on quality of care and quality of data leads innovative organizations and fiscally focused executives to increasingly turn to the cancer registry
  • 2. Introduction: Accountable Care, the Bottom Line and the Cancer Registry Recently profiled in the April 23, 2013 New York Times article, “A Health Provider Strives to Keep Hospital Beds Empty,” Advocate Health Care has embraced accountable care and has already achieved a two percent cost savings as a direct result. According to the article, thus far, hospital admissions are down six percent, and days spent in the hospital are down nearly nine percent. To facilitate the change, “Advocate has hired scores of workers to coordinate care and keep an eye on the highest-cost patients...” According to the same NY Times article, an estimated 428 accountable-care organizations now cover four million Medicare enrollees and millions more people with private insurance. While many pundits believe the accountable care movement could be the most meaningful recent development in the effort to fix our nation’s health care industry, hospital executives are only beginning to open their eyes to the powerful role their cancer registries can play in the quest for profitability during and beyond the transition. Critically important, the quality of data collection directly affects patient outcomes and reimbursement, and executives should take a few simple steps today to assess the quality of their cancer registry data, begin to use it more effectively and improve future financial performance. Data quality’s impact on patient care, outcomes and the bottom line Suspect data affects patient outcomes, and in accountable care organizations this also harms financial performance. Accountable care organizations link payments to quality improvements and cost reductions, a practice that will spread to cancer care soon. The deeper hospitals move into pay for performance, the more data their executives will need to prove quality of care. 1 Executives should take the time to examine the sources of their organizations’ data and how they acquire and report that data. Turning to the best data sources can boost reimbursement and financial performance of cancer centers and their parent organizations, and the best source for data related to cancer is undoubtedly the cancer registry department. Cancer registries already maintain the highest quality data Throughout the industry, the many ways organizations have begun to harness cancer registry data speaks to their confidence in the quality of that data. At some of the hospitals and health networks that work with Care Communications to ensure efficiency and effectiveness in cancer registry departments, cancer registry data has been effectively put to use in many different ways. Already, organizations use cancer registry data to justify new investments in technology or medical expertise. Many use the data to grade their own cancer center’s performance against benchmarks, determine if patients receive appropriate treatment, and educate physicians on what standards of care should be. In other instances, organizations use the data to analyze referral patterns or better understand their customer base. As more organizations begin to understand the value of this data as a competitive advantage for critical analysis and decision making, the industry’s growing confidence in the quality of data from the cancer registry will most likely only continue to rise. This makes perfect sense, considering the origin of that data. Abstracted by trained professionals, the cancer registry is a reliable, yet under-utilized source of cancer outcomes data. To ensure data quality standards, cancer registries remain highly regulated but offer the flexibility to be easily expanded in an organization’s efforts to collect additional helpful information and data that can further enhance patient care or the organization’s bottom line.
  • 3. the heightened quality of data housed in cancer registries can deliver a positive impact on efforts to reduce costs and improve reimbursement. The cancer registry should already be positioned to help the organization, because it can efficiently provide all required outcomes data. Unfortunately, many organizations mistakenly overlook the cancer registry as a quality data source and waste extensive time and resources by recreating much of the same data. Beyond outcomes data, the cancer registry can be used to determine outbound and inbound patient referrals, which can provide an accurate assessment of both lost and realized opportunity. For example, if the organization has referred numerous patients to a nearby breast surgeon for appropriate treatment, then perhaps the organization should consider hiring a breast surgeon. This could help ensure that the patient can receive treatment with the organization managing their care. Similarly, if the cancer registry data shows numerous inbound referrals for specific treatments, there may be an opportunity to expand this part of the organization to ensure effective, timely treatment for patients. By taking simple steps today, including asking a few simple questions to assess the current state of the cancer registry, the already impressive quality of cancer registry data can be further improved, along with its impact on tomorrow’s bottom line. Cancer registry now the definitive source for cancer outcomes data The cancer registry exists as the timeliest, most complete and most accurate data source for most accredited cancer programs and should be every executive’s preferred source for all cancer-related outcomes data. Revised in 2012, the ACoS CoC standards shifted the focus of the standards to the quality of patient care and enhanced the reporting of cancer data to include concurrent abstracting options with the introduction of the Rapid Quality Reporting Systemiii (RQRS). Cancer registries... (cont’d) 2 Turning to the cancer registry as a trusted source for data ensures quality, thanks to the American College of Surgeons (ACoS) Commission on Cancer (CoC) and its stringent regulations on data quality. Its published standards for data qualityi require all case abstracting to be performed by a Certified Tumor Registrar (CTR) in a timely manner (90 percent of cases are abstracted within six months of the date of first contact with the program). The standards also present mandated follow-up rates of 80 percent for all patients and 90 percent for recent patients, as well as requirements for data quality and submission to the National Cancer Data Base (NCDB). The high quality data ensured by this governance improves reimbursement and reduces costs, particularly in an accountable care environment. So, consider who is in charge of collecting the data. Cancer registry data is collected by highly trained Certified Tumor Registrars who have met increasingly strenuous educational requirements, including passing a national certification exam. The CTR certification marks its 30th anniversary in 2013, a testament to the stability and long-term contributions of these highly trained professionals. Once the certification is obtained, registrars must meet continuing education requirements to maintain the CTR credential. CTRs are trained to: “...correctly interpret and code cancer diagnosis, stage, treatment, and outcomes information for each case...”ii The use of CTRs for data abstraction ensures that cancer registry data is of the highest quality and executives can trust the data as a reliable source for informed decision making and utilize it to assist in meeting quality parameters in multiple settings. Value of the cancer registry to the bottom line Executives should understand what data their cancer registry contains and how that data can be easily extracted and used to help patients and improve the organization’s bottom line. Since data quality directly impacts patient outcomes,
  • 4. to reduce costs and improve patient outcomes and organizational performance already exists in the cancer registry. Beyond accessing existing data, new fields can be added to the cancer registry data collection process to ensure that any additional required data is accessible moving forward. Simple steps today, financial rewards tomorrow The cancer registry data assessment will help executives better understand the current state of their organizations’ cancer registry and what cancer registry data can do for their organizations today. With a solid understanding of the starting point in hand, executives should take the following steps to further enhance the usefulness and future potential of the cancer registry to improve an organization’s performance in a variety of ways. 1 Develop standard reports for data analysis. These reports can be custom designed on any data parameter collected by the cancer registry and can aid in understanding the who, what, when, where, why and how of an organization’s cancer program. 2 (Executives) Become active and involved in cancer committee meetings where these reports can be presented. Decisions on program development and improvement can be made given your active involvement in both data analysis review and cancer committee attendance. 3 Ask for data. Executives are often surprised to discover the amount of data available to them that can aid in their decision making processes. 4 Before conducting a study or chart review on cancer care, seek out the assistance of your cancer registry. Duplication of effort can be avoided, and many resources can be applied to other more useful efforts. Cancer registry now... (cont’d) Prior to the institution of the RQRS, providers received information 18-24 months after treatment rendering the treatment information insufficient to assess quality of care. To address these issues the CoC adopted the RQRS. Currently voluntary, RQRS could become mandatory in the future, which would require accredited cancer programs to report data on patients concurrently and notify hospitals of treatment expectations. Each hospital would then receive its year-to-date concordance rate relative to other similar hospitals at the local, state and national levels. The CoC has a data use agreement in place to use the clinical information provided by the RQRS for the purposes of quality review and improvement. The revised CoC standards assist hospitals with health care operations, including quality assurance, utilization review and accreditation. As a result, the cancer registry now provides the most accurate and complete source of data on cancer treatment and outcomes available to many health care executives. Quickly assess the organization’s cancer registry data To quickly assess the quality of an organization’s cancer registry data and its potential to boost organizational performance today, executives should work with their teams to answer four simple questions: 1 What data do we currently have access to through the cancer registry? 2 What data has been required in the past and is it relevant for use today? 3 What data is needed today in light of new accountability and reporting standards? 4 What, if any, additional data points should we begin collecting to strengthen the registry’s stature as a tool to build the bottom line? As executives answer these questions, it should become obvious that much of the data they need 3
  • 5. Simple steps today... (cont’d) 5 Monitor timeliness of treatment. If the average delay between diagnosis and the start of treatment is extended, it could signal a communications breakdown between specialties or a shortage of appointment openings for treatment, and this could be an opportunity for a fast tracking program. 6 Monitor the treatment mix for the primary facilities. Does the treatment mix mirror national trends? If not, it could mean that patients aren’t being informed of all their options before deciding on a course of treatment; perhaps there is a need for a more thorough patient consultation program. 7 Examine average stage of disease at diagnosis. Are the organization’s patients being diagnosed at later stages of disease than the benchmarks established at the local, state, or national level? If so, the community may need an early screening program to provide patients and primary care physicians with a better education on early detection. 8 Monitor patient ages. Determine the primary age groups of patients and compare them to previous data to see if the average age has changed. This will help in planning and scheduling support programs for different patient age groups. 9 Analyze the success of signature services. Using rapid reporting mechanisms such as the RQRS, executives can compare patients who are eligible for signature services to those who are using them to determine whether the services should be grown (marketed, referred and staffed) or discontinued. 10 Review patient addresses. By taking a close look at patient addresses, the organization can identify areas where few or no patients reside, potentially signaling an opportunity for extended community and primary care physician outreach.   References: i Commission on Cancer. Cancer Program Standards 2012: Ensuring Patient-Centered Care. American College of Surgeons. http://www.facs.org/cancer/ coc/programstandards2012.pdf. Published September, 2012. Accessed May 20, 2013. ii Commission on Cancer. Cancer Program Standards 2012: Ensuring Patient-Centered Care. American College of Surgeons. http://www.facs.org/cancer/ coc/programstandards2012.pdf. Published September, 2012. Accessed May 20, 2013. iii Commission on Cancer. The Rapid Quality Reporting System. American College of Surgeons. http://www.facs.org/cancer/ncdb/rqrs0509.pdf Published April, 2009. Accessed May 20, 2013. 4
  • 6. About the Author Laurie Hebert, RHIA, CCS, CCS-P, CTR Vice President and General Manager, Cancer Registry Services 800-458-3544, ext. 161 lhebert@care-communications.com www.carecommunications.com/cancer_registry As Vice President and General Manager, Cancer Registry Services at Care Communications, Inc., Laurie Hebert is responsible for managing client relationships, cancer registry consultants, and sales of cancer registry services. Hebert also provides input and required oversight for research projects that require cancer registry data. With over 20 years of experience, Hebert has worked at various hospitals and cancer registry facilities in a wide range of health information management (HIM) roles. She has published or contributed to many articles noted in national trade publications, authored white papers related to the cancer registry field, co-authored a study on pediatric lymphoma, and assisted in the development of a pediatric staging form chosen by the American College of Surgeons Commission on Cancer as a best practice tool for pediatric facilities. Hebert is currently serving on the National Cancer Registrars Association’s (NCRA) Board of Directors as Advocacy and Technical Practice Director-Midwest along with serving on several additional NCRA related committees, and is the past chair of the association’s National Cancer Registrars Week Committee. She is past president-elect of the Central Louisiana Health Information Management Association and past president of the Southeast Louisiana Health Information Management Association. Hebert is a member of several health care associations including the American Health Information Management Association (AHIMA), National Cancer Registrars Association, Louisiana Health Information Management Association (LHIMA), the Southwest Louisiana Health Information Management Association (SWLHIMA) and the Louisiana Cancer Registrars Association (LCRA). She received a bachelor’s degree in psychology and HIM from the University of Southwestern Louisiana. Areas of Expertise: l Cancer registry regulations and accreditation l Cancer registry education and advocacy l Data management and analysis l Quality data collection l Cancer studies l Outcomes measurement l Database outcomes improvement 5